"Even at low-doses, CDDO-Im induces cell protecting genes, inhibits DNA damage by aflatoxin and dramatically blocks development of liver tumors," according to Melinda Yates of Johns Hopkins University and lead author of the study.
As described in their study, laboratory rats were given CDDO-Im three days per week for three weeks, with doses ranging from from 1 to 100 ìmol/kg body weight.Beginning one week after the start of CDDO-Im, they were given daily doses over a two-week period of aflatoxin B1, a known cancer-causing agent produced by molds in stored agricultural crops.
Aside from the significant reduction in liver tumor formation, the scientists also confirmed that CDDO-Im activated Nrf2, a gene that acts as a master regulator of the majority of antioxidant pathways and detoxifying enzymes for environmental pollutants.
"The unparalleled potency of CDDO-Im in rats highlights the chemopreventive promise of targeting Nrf2 pathways with triterpenoids, and provides a new direction for drug development," said Dr. Yates
Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Synthetic Triterpenoid, CDDO-Imidazole Abstract # 2497, Melinda Yates
and Thomas Kensler, John Hopkins University
, Baltimore, Md.